tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CDTX Stock Latest News

Cidara Therapeutics’ Earnings Call Highlights CD388 Progress
Company AnnouncementsCidara Therapeutics’ Earnings Call Highlights CD388 Progress
4d ago
CDTX
Cidara Therapeutics price target raised to $145 from $137 at RBC Capital
PremiumThe Fly
Cidara Therapeutics price target raised to $145 from $137 at RBC Capital
6d ago
CDTX
Positive Outlook on Cidara Therapeutics: Progress in CD388 Flu Program and Strategic Trial Advancements
PremiumRatings
Positive Outlook on Cidara Therapeutics: Progress in CD388 Flu Program and Strategic Trial Advancements
6d ago
CDTX
Cidara Therapeutics Advances CD388 with Phase 3 Expansion
PremiumCompany Announcements
Cidara Therapeutics Advances CD388 with Phase 3 Expansion
6d ago
CDTX
Cidara Therapeutics reports Q3 EPS ($3.10), consensus ($1.33)
PremiumThe Fly
Cidara Therapeutics reports Q3 EPS ($3.10), consensus ($1.33)
7d ago
CDTX
CDTX Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsCDTX Upcoming Earnings Report: What to Expect?
9d ago
CDTX
Cidara Therapeutics’ CD388 Study: A Potential Game-Changer in Influenza Prevention
Premium
Company Announcements
Cidara Therapeutics’ CD388 Study: A Potential Game-Changer in Influenza Prevention
16d ago
CDTX
H.C. Wainwright reiterates Cidara as top pick after influenza data
Premium
The Fly
H.C. Wainwright reiterates Cidara as top pick after influenza data
21d ago
CDTX
Cidara Therapeutics announces presentation on CD388 at ESWI Conference
PremiumThe Fly
Cidara Therapeutics announces presentation on CD388 at ESWI Conference
21d ago
CDTX
Promising Phase 2b Results for Cidara’s CD388 Justify Buy Rating Amidst Strong Preventive Efficacy Against Influenza
PremiumRatings
Promising Phase 2b Results for Cidara’s CD388 Justify Buy Rating Amidst Strong Preventive Efficacy Against Influenza
23d ago
CDTX
Cidara Therapeutics announces Phase 2b presentation on CD388 at ID Week 2025
PremiumThe Fly
Cidara Therapeutics announces Phase 2b presentation on CD388 at ID Week 2025
23d ago
CDTX
Cidara Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe Fly
Cidara Therapeutics initiated with an Overweight at Morgan Stanley
28d ago
CDTX
Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
PremiumRatingsBuy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
28d ago
CDTX
Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
Premium
The Fly
Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
1M ago
ABT
MOS
Cidara Therapeutics initiated with an Overweight at JPMorgan
Premium
The Fly
Cidara Therapeutics initiated with an Overweight at JPMorgan
1M ago
CDTX
Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating
PremiumRatings
Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating
1M ago
CDTX
Cidara Therapeutics price target raised to $150 from $110 at H.C. Wainwright
PremiumThe Fly
Cidara Therapeutics price target raised to $150 from $110 at H.C. Wainwright
1M ago
CDTX
Cidara Therapeutics: Strong Buy Rating Backed by Breakthrough Therapy Designation and Promising CD388 Efficacy
PremiumRatings
Cidara Therapeutics: Strong Buy Rating Backed by Breakthrough Therapy Designation and Promising CD388 Efficacy
1M ago
CDTX
Cidara Therapeutics receives U.S. FDA BTD for CD388
PremiumThe Fly
Cidara Therapeutics receives U.S. FDA BTD for CD388
1M ago
CDTX
Cidara Therapeutics price target raised to $173 from $153 at Citizens JMP
PremiumThe FlyCidara Therapeutics price target raised to $173 from $153 at Citizens JMP
1M ago
CDTX
Closing Bell Movers: Rumble jumps 11% on Perplexity partnership
Premium
The Fly
Closing Bell Movers: Rumble jumps 11% on Perplexity partnership
1M ago
CF
CLS
Cidara Therapeutics announces $339M BARDA award
Premium
The Fly
Cidara Therapeutics announces $339M BARDA award
1M ago
CDTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >